Intervention/treatment:
Genetic: Low dose LX2006
Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
Genetic: High Dose LX2006
Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)
Thursday, July 7, 2022
A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia
ClinicalTrials.gov Identifier: NCT05445323;
Sponsor: Lexeo Therapeutics
Subscribe to:
Posts (Atom)
